Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $240 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $240.
September 14, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Alnylam Pharmaceuticals and maintained a price target of $240.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a high price target indicates strong confidence in the company's stock. This could potentially lead to increased investor interest and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100